Nanoparticle surface properties and their role at the intestinal interface: transport and cellular uptake
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Anselmo AC, Gokarn Y, Mitragotri S (2019) Non-invasive delivery strategies for biologics. Nat Rev Drug Discov 18:19–4010.1038/nrd.2018.183 ↗
2. Baryakova TH, Pogostin BH, Langer R, McHugh KJ (2023) Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov 22:387–40910.1038/s41573-023-00670-0 ↗
3. Hua S (2020) Advances in oral drug delivery for regional targeting in the gastrointestinal tract - influence of physiological, pathophysiological and pharmaceutical factors. Front Pharmacol 11:52410.3389/fphar.2020.00524 ↗
4. Ensign LM, Cone R, Hanes J (2012) Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 64:557–57010.1016/j.addr.2011.12.009 ↗
5. Li AP (2001) Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today 6:357–36610.1016/S1359-6446(01)01712-3 ↗
6. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–71510.1038/nrd1470 ↗
7. Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM et al (2015) An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov 14:475–48610.1038/nrd4609 ↗
8. Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33:941–95110.1038/nbt.3330 ↗
9. Gulati NM, Stewart PL, Steinmetz NF (2018) Bioinspired shielding strategies for nanoparticle drug delivery applications. Mol Pharm 15:2900–290910.1021/acs.molpharmaceut.8b00292 ↗
10. Harde H, Das M, Jain S (2011) Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv 8:1407–142410.1517/17425247.2011.604311 ↗
11. Wang Y, Pi C, Feng X, Hou Y, Zhao L, Wei Y (2020) The influence of nanoparticle properties on oral bioavailability of drugs. Int J Nanomedicine 15:6295–631010.2147/IJN.S257269 ↗
12. Kamaly N, Yameen B, Wu J, Farokhzad OC (2016) Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev 116:2602–266310.1021/acs.chemrev.5b00346 ↗
13. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R (2021) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 20:101–12410.1038/s41573-020-0090-8 ↗
14. Navya PN, Daima HK (2016) Rational engineering of physicochemical properties of nanomaterials for biomedical applications with nanotoxicological perspectives. Nano Converg 3:110.1186/s40580-016-0064-z ↗
15. Nel AE, Mädler L, Velegol D, Xia T, Hoek EMV, Somasundaran P et al (2009) Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 8:543–55710.1038/nmat2442 ↗
16. Yao M, He L, McClements DJ, Xiao H (2015) Uptake of gold nanoparticles by intestinal epithelial cells: impact of particle size on their absorption, accumulation, and toxicity. J Agric Food Chem 63:8044–804910.1021/acs.jafc.5b03242 ↗
17. Bandi SP, Kumbhar YS, Venuganti VVK (2020) Effect of particle size and surface charge of nanoparticles in penetration through intestinal mucus barrier. J Nanopart Res. https://doi.org/10.1007/s11051-020-04785-y10.1007/s11051-020-04785-y ↗
18. Fröhlich E (2012) The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine 7:5577–559110.2147/IJN.S36111 ↗
19. Verma A, Stellacci F (2010) Effect of surface properties on nanoparticleâcell interactions. Small 6:12–2110.1002/smll.200901158 ↗
20. Shan W, Zhu X, Liu M, Li L, Zhong J, Sun W et al (2015) Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin. ACS Nano 9:2345–235610.1021/acsnano.5b00028 ↗
21. Wang Y-Y, Lai SK, Suk JS, Pace A, Cone R, Hanes J (2008) Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “slip” through the human mucus barrier. Angew Chem Int Ed Engl 47:9726–972910.1002/anie.200803526 ↗
22. Lai SK, Wang Y-Y, Hanes J (2009) Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61:158–17110.1016/j.addr.2008.11.002 ↗
23. Xu Q, Ensign LM, Boylan NJ, Schön A, Gong X, Yang J-C et al (2015) Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo. ACS Nano 9:9217–922710.1021/acsnano.5b03876 ↗
24. Guo Y, Ma Y, Chen X, Li M, Ma X, Cheng G et al (2023) Mucus penetration of surface-engineered nanoparticles in various pH microenvironments. ACS Nano 17:2813–282810.1021/acsnano.2c11147 ↗
25. Sato H (2025) Development of nanoparticle-based mucosal drug delivery systems for controlling pharmacokinetic behaviors. Biol Pharm Bull 48:759–76810.1248/bpb.b25-00071 ↗
26. Olivares-Morales A, Lennernäs H, Aarons L, Rostami-Hodjegan A (2015) Translating human effective jejunal intestinal permeability to surface-dependent intrinsic permeability: a pragmatic method for a more mechanistic prediction of regional oral drug absorption. AAPS J 17:1177–119210.1208/s12248-015-9758-0 ↗
27. Ohno H (2016) Intestinal M cells. J Biochem 159:151–16010.1093/jb/mvv121 ↗
28. Ermund A, Gustafsson JK, Hansson GC, Keita AV (2013) Mucus properties and goblet cell quantification in mouse, rat and human ileal Peyer’s patches. PLoS ONE 8:e8368810.1371/journal.pone.0083688 ↗
29. Sonaje K, Lin K-J, Tseng MT, Wey S-P, Su F-Y, Chuang E-Y et al (2011) Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins. Biomaterials 32:8712–872110.1016/j.biomaterials.2011.07.086 ↗
30. Lamson NG, Berger A, Fein KC, Whitehead KA (2020) Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability. Nat Biomed Eng 4:84–9610.1038/s41551-019-0465-5 ↗
31. He Y, Cheng M, Yang R, Li H, Lu Z, Jin Y et al (2023) Research progress on the mechanism of nanoparticles crossing the intestinal epithelial cell membrane. Pharmaceutics 15:181610.3390/pharmaceutics15071816 ↗
32. Coméra C, Cartier C, Gaultier E, Catrice O, Panouille Q, El Hamdi S et al (2020) Jejunal villus absorption and paracellular tight junction permeability are major routes for early intestinal uptake of food-grade TiO2 particles: an in vivo and ex vivo study in mice. Part Fibre Toxicol 17:2610.1186/s12989-020-00357-z ↗
33. Nyström EEL, Martinez-Abad B, Arike L, Birchenough GMH, Nonnecke EB, Castillo PA et al (2021) An intercrypt subpopulation of goblet cells is essential for colonic mucus barrier function. Science. 372:eabb159010.1126/science.abb1590 ↗
34. Round AN, Rigby NM, de la Garcia Torre A, Macierzanka A, Mills ENC, Mackie AR (2012) Lamellar structures of MUC2-rich mucin: a potential role in governing the barrier and lubricating functions of intestinal mucus. Biomacromol 13:3253–326110.1021/bm301024x ↗
35. McCright J, Sinha A, Maisel K (2022) Generating an in vitro gut model with physiologically relevant biophysical mucus properties. Cell Mol Bioeng 15:479–49110.1007/s12195-022-00740-0 ↗
36. Qiao X, Bao L, Liu G, Cui X (2024) Nanomaterial journey in the gut: from intestinal mucosal interaction to systemic transport. Nanoscale 16:19207–1922010.1039/D4NR02480J ↗
37. Meldrum OW, Yakubov GE (2025) Journey of dietary fiber along the gastrointestinal tract: role of physical interactions, mucus, and biochemical transformations. Crit Rev Food Sci Nutr 65:4264–429210.1080/10408398.2024.2390556 ↗
38. Ermund A, Schütte A, Johansson MEV, Gustafsson JK, Hansson GC (2013) Studies of mucus in mouse stomach, small intestine, and colon. I. Gastrointestinal mucus layers have different properties depending on location as well as over the Peyer’s patches. Am J Physiol Gastrointest Liver Physiol 305:G341–G34710.1152/ajpgi.00046.2013 ↗
39. Atuma C, Strugala V, Allen A, Holm L (2001) The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 280:G922–G92910.1152/ajpgi.2001.280.5.G922 ↗
40. Abdulkarim M, Agulló N, Cattoz B, Griffiths P, Bernkop-Schnürch A, Borros SG et al (2015) Nanoparticle diffusion within intestinal mucus: three-dimensional response analysis dissecting the impact of particle surface charge, size and heterogeneity across polyelectrolyte, pegylated and viral particles. Eur J Pharm Biopharm 97:230–23810.1016/j.ejpb.2015.01.023 ↗
41. Subramanian DA, Langer R, Traverso G (2022) Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems. J Nanobiotechnology 20:36210.1186/s12951-022-01539-x ↗
42. Paone P, Cani PD (2020) Mucus barrier, mucins and gut microbiota: the expected slimy partners? Gut 69:2232–224310.1136/gutjnl-2020-322260 ↗
43. Li H, Limenitakis JP, Fuhrer T, Geuking MB, Lawson MA, Wyss M et al (2015) The outer mucus layer hosts a distinct intestinal microbial niche. Nat Commun 6:829210.1038/ncomms9292 ↗
44. Luis AS, Hansson GC (2023) Intestinal mucus and their glycans: a habitat for thriving microbiota. Cell Host Microbe 31:1087–110010.1016/j.chom.2023.05.026 ↗
45. Tjakra M, Chakrapeesirisuk N, Jacobson M, Sellin ME, Eriksson J, Teleki A et al (2025) Optimized artificial colonic mucus enabling physiologically relevant diffusion studies of drugs, particles, and delivery systems. Mol Pharm 22:4032–404510.1021/acs.molpharmaceut.5c00298 ↗
46. Wang Y, Mo Y, Sun Y, Li J, An Y, Feng N et al (2024) Intestinal nanoparticle delivery and cellular response: a review of the bidirectional nanoparticle-cell interplay in mucosa based on physiochemical properties. J Nanobiotechnology 22:66910.1186/s12951-024-02930-6 ↗
47. Villegas-Novoa C, Wang Y, Sims CE, Allbritton NL (2024) Creation of a spatially complex mucus bilayer on an in vitro colon model. Sci Rep 14:1684910.1038/s41598-024-67591-9 ↗
48. Damianos JA, Camilleri M (2025) Mucus as part of the intestinal barrier in neurological diseases. J Exp Neurol 6:142–15110.33696/Neurol.6.117 ↗
49. Lamas B, Martins Breyner N, Houdeau E (2020) Impacts of foodborne inorganic nanoparticles on the gut microbiota-immune axis: potential consequences for host health. Part Fibre Toxicol 17:1910.1186/s12989-020-00349-z ↗
50. van den Brule S, Ambroise J, Lecloux H, Levard C, Soulas R, De Temmerman P-J et al (2016) Dietary silver nanoparticles can disturb the gut microbiota in mice. Part Fibre Toxicol 13:3810.1186/s12989-016-0149-1 ↗
51. Javurek AB, Suresh D, Spollen WG, Hart ML, Hansen SA, Ellersieck MR, et al (2017) Gut dysbiosis and neurobehavioral alterations in rats exposed to silver nanoparticles. Sci Rep 7:2822. https://doi.org/10.1038/s41598-017-02880-010.1038/s41598-017-02880-0 ↗
52. Ren Q, Ma J, Li X, Meng Q, Wu S, Xie Y et al (2023) Intestinal toxicity of metal nanoparticles: silver nanoparticles disorder the intestinal immune microenvironment. ACS Appl Mater Interfaces 15:27774–2778810.1021/acsami.3c05692 ↗
53. Balasubramanian S, Haneen MA, Sharma G, Perumal E (2024) Acute copper oxide nanoparticles exposure alters zebrafish larval microbiome. Life Sci 336:12231310.1016/j.lfs.2023.122313 ↗
54. Abubakari A, Salvador-Oke KT, M-Kamal HS, Johnson AM (2025) Microbial membrane vesicles and the intestinal epithelium: a crosstalk in health and disease. Arch Microbiol 208:310.1007/s00203-025-04562-2 ↗
55. Dwivedi AD, Ma LQ (2014) Biocatalytic synthesis pathways, transformation, and toxicity of nanoparticles in the environment. Crit Rev Environ Sci Technol 44:1679–173910.1080/10643389.2013.790747 ↗
56. Vitulo M, Gnodi E, Meneveri R, Barisani D (2022) Interactions between nanoparticles and intestine. Int J Mol Sci 23:433910.3390/ijms23084339 ↗
57. Coreas R, Cao X, Deloid GM, Demokritou P, Zhong W (2020) Lipid and protein corona of food-grade TiO2 nanoparticles in simulated gastrointestinal digestion. NanoImpact 20:10027210.1016/j.impact.2020.100272 ↗
58. Zhang T, Zhu G, Lu B, Qian Z, Peng Q (2020) Protein corona formed in the gastrointestinal tract and its impacts on oral delivery of nanoparticles. Med Res Rev 41:1835–185010.1002/med.21767 ↗
59. Antonello G, Marucco A, Gazzano E, Kainourgios P, Ravagli C, Gonzalez-Paredes A et al (2022) Changes of physico-chemical properties of nano-biomaterials by digestion fluids affect the physiological properties of epithelial intestinal cells and barrier models. Part Fibre Toxicol 19:4910.1186/s12989-022-00491-w ↗
60. Abdelkhaliq A, van der Zande M, Punt A, Helsdingen R, Boeren S, Vervoort JJM et al (2018) Impact of nanoparticle surface functionalization on the protein corona and cellular adhesion, uptake and transport. J Nanobiotechnology 16:7010.1186/s12951-018-0394-6 ↗
61. Di Silvio D, Rigby N, Bajka B, Mackie A, Baldelli Bombelli F (2016) Effect of protein corona magnetite nanoparticles derived from bread in vitro digestion on Caco-2 cells morphology and uptake. Int J Biochem Cell Biol 75:212–22210.1016/j.biocel.2015.10.019 ↗
62. Rejman J, Oberle V, Zuhorn IS, Hoekstra D (2004) Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 377:159–16910.1042/bj20031253 ↗
63. Zhang S, Gao H, Bao G (2015) Physical principles of nanoparticle cellular endocytosis. ACS Nano 9:8655–867110.1021/acsnano.5b03184 ↗
64. Lin J, Miao L, Zhong G, Lin C-H, Dargazangy R, Alexander-Katz A (2020) Understanding the synergistic effect of physicochemical properties of nanoparticles and their cellular entry pathways. Commun Biol 3:20510.1038/s42003-020-0917-1 ↗
65. Rennick JJ, Johnston APR, Parton RG (2021) Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat Nanotechnol 16:266–27610.1038/s41565-021-00858-8 ↗
66. Iversen T-G, Skotland T, Sandvig K (2011) Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nano Today 6:176–18510.1016/j.nantod.2011.02.003 ↗
67. Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin F-H et al (2019) Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res 23:2010.1186/s40824-019-0166-x ↗
68. Sun S-J, Liu Y-T, Nie J-Y, Hu Z-Y, Liu Z-R, Chen H et al (2025) Advances and challenges in research methods on oral absorption mechanisms of nano-formulations. PeerJ 13:e2003210.7717/peerj.20032 ↗
69. Zhang Y, Wang Y, Lu Y, Quan H, Wang Y, Song S et al (2025) Advanced oral drug delivery systems for gastrointestinal targeted delivery: the design principles and foundations. J Nanobiotechnology 23:40010.1186/s12951-025-03479-8 ↗
70. Nguyen PL, Liu B, Zhang S, Hao J, Yu J (2025) Macropinocytosis and fast endophilin-mediated endocytosis mediate absorption of garlic chive-derived vesicle-like nanoparticles in human intestinal epithelial cells. Mol Pharm 22:3935–394810.1021/acs.molpharmaceut.5c00190 ↗
71. Damian-Buda A-I, Boccaccini AR (2025) Shedding light on the cellular uptake mechanisms of bioactive glass nanoparticles as controlled intracellular delivery platforms: a review of the recent literature. Adv Healthc Mater 15:e0275410.1002/adhm.202502754 ↗
72. Ho YT, Kamm RD, Kah JCY (2018) Influence of protein corona and caveolae-mediated endocytosis on nanoparticle uptake and transcytosis. Nanoscale 10:12386–1239710.1039/C8NR02393J ↗
73. Ray S, Moonshi SS, Ta HT (2025) “therapies through gut:” targeted drug delivery for non-gastrointestinal diseases by oral administration. Adv Healthc Mater 14:e240316210.1002/adhm.202403162 ↗
74. Cho H, Huh KM, Cho HJ, Kim B, Shim MS, Cho Y-Y et al (2024) Beyond nanoparticle-based oral drug delivery: transporter-mediated absorption and disease targeting. Biomater Sci 12:3045–306710.1039/D4BM00313F ↗
75. Hansen ME, Ibrahim Y, Desai TA, Koval M (2024) Nanostructure-mediated transport of therapeutics through epithelial barriers. Int J Mol Sci 25:709810.3390/ijms25137098 ↗
76. Bamigbade GB, Abdin M, Subhash A, Arachchi MP, Ullah N, Gan R-Y et al (2025) Plant polysaccharide-capped nanoparticles: a sustainable approach to modulate gut microbiota and advance functional food applications. Compr Rev Food Sci Food Saf 24:e7015610.1111/1541-4337.70156 ↗
77. Zheng G, Zhang B, Yu H, Song Z, Xu X, Zheng Z et al (2025) Therapeutic applications and potential biological barriers of nano-delivery systems in common gastrointestinal disorders: a comprehensive review. Adv Compos Hybrid Mater. https://doi.org/10.1007/s42114-025-01292-310.1007/s42114-025-01292-3 ↗
78. Meng H, Yang S, Li Z, Xia T, Chen J, Ji Z et al (2011) Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent macropinocytosis mechanism. ACS Nano 5:4434–444710.1021/nn103344k ↗
79. Li Y-X, Pang H-B (2021) Macropinocytosis as a cell entry route for peptide-functionalized and bystander nanoparticles. J Control Release 329:1222–123010.1016/j.jconrel.2020.10.049 ↗
80. Brayden DJ, Jepson MA, Baird AW (2005) Keynote review: intestinal Peyer’s patch M cells and oral vaccine targeting. Drug Discov Today 10:1145–115710.1016/S1359-6446(05)03536-1 ↗
81. Gebert A, Steinmetz I, Fassbender S, Wendlandt K-H (2004) Antigen transport into Peyer’s patches: increased uptake by constant numbers of M cells. Am J Pathol 164:65–7210.1016/S0002-9440(10)63097-0 ↗
82. Azizi A, Kumar A, Diaz-Mitoma F, Mestecky J (2010) Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog 6:e100114710.1371/journal.ppat.1001147 ↗
83. Ramazani A, Mandal T, Larson RG (2016) Modeling the hydrophobicity of nanoparticles and their interaction with lipids and proteins. Langmuir 32:13084–13094. https://doi.org/10.1021/acs.langmuir.6b0196310.1021/acs.langmuir.6b01963 ↗
84. Fievez V, Plapied L, des Rieux A, Pourcelle V, Freichels H, Wascotte V et al (2009) Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur J Pharm Biopharm 73:16–2410.1016/j.ejpb.2009.04.009 ↗
85. Vllasaliu D, Exposito-Harris R, Heras A, Casettari L, Garnett M, Illum L et al (2010) Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. Int J Pharm 400:183–19310.1016/j.ijpharm.2010.08.020 ↗
86. Yeh T-H, Hsu L-W, Tseng MT, Lee P-L, Sonjae K, Ho Y-C et al (2011) Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials 32:6164–617310.1016/j.biomaterials.2011.03.056 ↗
87. Rosenthal R, Günzel D, Finger C, Krug SM, Richter JF, Schulzke J-D et al (2012) The effect of chitosan on transcellular and paracellular mechanisms in the intestinal epithelial barrier. Biomaterials 33:2791–280010.1016/j.biomaterials.2011.12.034 ↗
88. de Sousa Almeida M, Susnik E, Drasler B, Taladriz-Blanco P, Petri-Fink A, Rothen-Rutishauser B (2021) Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem Soc Rev 50:5397–543410.1039/D0CS01127D ↗
89. Georgieva JV, Kalicharan D, Couraud P-O, Romero IA, Weksler B, Hoekstra D et al (2011) Surface characteristics of nanoparticles determine their intracellular fate in and processing by human blood-brain barrier endothelial cells in vitro. Mol Ther 19:318–32510.1038/mt.2010.236 ↗
90. Banerjee A, Berezhkovskii A, Nossal R (2016) Kinetics of cellular uptake of viruses and nanoparticles via clathrin-mediated endocytosis. Phys Biol 13:01600510.1088/1478-3975/13/1/016005 ↗
91. Muro S, Schuchman EH, Muzykantov VR (2006) Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol Ther 13:135–14110.1016/j.ymthe.2005.07.687 ↗
92. Lu W, Xiong C, Zhang R, Shi L, Huang M, Zhang G et al (2012) Receptor-mediated transcytosis: a mechanism for active extravascular transport of nanoparticles in solid tumors. J Control Release 161:959–96610.1016/j.jconrel.2012.05.014 ↗
93. Fröhlich E, Meindl C, Roblegg E, Ebner B, Absenger M, Pieber TR (2012) Action of polystyrene nanoparticles of different sizes on lysosomal function and integrity. Part Fibre Toxicol 9:2610.1186/1743-8977-9-26 ↗
94. Soukar J, Peppas NA, Gaharwar AK (2025) Organelle-targeting nanoparticles. Adv Sci (Weinh) 12:e241172010.1002/advs.202411720 ↗
95. Halamoda-Kenzaoui B, Ceridono M, Urbán P, Bogni A, Ponti J, Gioria S et al (2017) The agglomeration state of nanoparticles can influence the mechanism of their cellular internalisation. J Nanobiotechnology 15:4810.1186/s12951-017-0281-6 ↗
96. He K, Yan X, Li N, Dang S, Xu L, Zhao B et al (2015) Internalization of the TGF-β type I receptor into caveolin-1 and EEA1 double-positive early endosomes. Cell Res 25:738–75210.1038/cr.2015.60 ↗
97. Naota M, Shimada A, Morita T, Yamamoto Y, Inoue K, Takano H (2013) Caveolae-mediated endocytosis of intratracheally instilled gold colloid nanoparticles at the air-blood barrier in mice. Toxicol Pathol 41:487–49610.1177/0192623312457271 ↗
98. Zhang L, Yang X, Lv Y, Xin X, Qin C, Han X et al (2017) Cytosolic co-delivery of miRNA-34a and docetaxel with core-shell nanocarriers via caveolae-mediated pathway for the treatment of metastatic breast cancer. Sci Rep 7:4618610.1038/srep46186 ↗
99. Muro S, Cui X, Gajewski C, Murciano J-C, Muzykantov VR, Koval M (2003) Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol 285:C1339–C134710.1152/ajpcell.00099.2003 ↗
100. Vranic S, Boggetto N, Contremoulins V, Mornet S, Reinhardt N, Marano F et al (2013) Deciphering the mechanisms of cellular uptake of engineered nanoparticles by accurate evaluation of internalization using imaging flow cytometry. Part Fibre Toxicol 10:210.1186/1743-8977-10-2 ↗